VIGILINT

GLOBAL PROTECTION. DEDICATED CARE.

Webinar: SARS-COV-2 Omicron Variant of Concern

Join us on December 14th at 11 am EST/8 am PST for a webinar featuring VIGILINT Emergency Medicine Physicians Drs Ossmann and Cellini as they discuss the newly discovered omicron variant and the potential impact on holiday travel. You have questions, and we want to hear from you! Please submit … Read more about Webinar: SARS-COV-2 Omicron Variant of Concern

COVID-19 Vaccine for Children & The Pandemic’s Impact on Working Parents

COVID-19 Vaccine Approved for Children 5-11 Kids 5 and up can now get their age-appropriate dose of the COVID-19 vaccine, which is the most effective way to protect against the virus—hard stop. After a year that saw parents scrambling to find ways to protect their children from illness and keep … Read more about COVID-19 Vaccine for Children & The Pandemic’s Impact on Working Parents

COVID-19 ONE YEAR LATER, Part I: The Best and Worst Handlings of the COVID-19 Crisis

On January 10, 2020, VIGILINT first reported a new strain of a coronavirus connected to a cluster of pneumonia cases linked to Wuhan, China. No one could have predicted the year that would follow. As of publishing, worldwide cases have reached 104 million with 2.27 million deaths. VIGILINT … Read more about COVID-19 ONE YEAR LATER, Part I: The Best and Worst Handlings of the COVID-19 Crisis

COVID-19 Update: Convalescent Plasma

On Sunday, August 23, the US Federal Food and Drug Administration (FDA) announced an Emergency Use Authorization (EUA) for convalescent plasma as a treatment for hospitalized COVID-19 patients citing "known and potential benefits of the product outweigh the known and potential risks of the … Read more about COVID-19 Update: Convalescent Plasma

COVID-19 Update: The Race for a Vaccine

Vaccine development for COVID-19 is topic number one, and our collective hope for going back to "normal" dangle on that needle. The global race to market includes pharma's heavy hitters like Pfizer, Johnson & Johnson, AstraZeneca, and Moderna, a Cambridge, Massachusetts-based company that … Read more about COVID-19 Update: The Race for a Vaccine

COVID-19 Update: The Disparity Between the US and the EU COVID-19 Experience

As the US topped a whopping 2.8 million cases and a death count of 130,000 last week, cities and towns across the nation canceled July 4th firework displays and large public gatherings in an effort to prevent further spread of COVID-19. The fervor for holiday travel was scaled down this past weekend … Read more about COVID-19 Update: The Disparity Between the US and the EU COVID-19 Experience

COVID-19 Update: What is the New Normal for Businesses?

Once the epicenter of the virus outbreak, the densely populated city of New York endured months of significantly high rates of confirmed infections and reported deaths. As cases began to steadily decrease in the month of May, Governor Cuomo's daily televised briefs became cautiously more hopeful. As … Read more about COVID-19 Update: What is the New Normal for Businesses?

VIGILINT ADVISES GLOBAL COMPANIES ON COVID-19 RETURN TO WORK STRATEGIES

May 11, 2020, Morrisville, NC:  VIGILINT, a global telemedicine and medical advisory company headquartered in Morrisville, was featured in The Wall Street Journal discussing risk mitigation strategies for global companies’ return-to-work programs.  VIGILINT’s Chief Medical Officer, Eric Ossmann, MD, … Read more about VIGILINT ADVISES GLOBAL COMPANIES ON COVID-19 RETURN TO WORK STRATEGIES

COVID-19 FACT SHEET WITH PHYSICIAN-RECOMMENDED PREVENTATIVE MEASURES

This page was last updated on May 5, 2020. Overview: The United States is experiencing sustained human-to-human transmission of the novel COVID-19 virus, first discovered in Wuhan, China in December 2019. Since then, every state in the US has confirmed cases, and new cases are emerging every day. … Read more about COVID-19 FACT SHEET WITH PHYSICIAN-RECOMMENDED PREVENTATIVE MEASURES